Storage Conditions
-20°C/1 year
Applications
ELISA
IF
IHC
WB
Concentration
1 mg/ml
Recomended Dilution
Western Blot: 1/500 - 1/2000. Immunohistochemistry: 1/100 - 1/300. ELISA: 1/10000. Not yet tested in other applications.
Type Clonality
Polyclonal
Immunogen
The antiserum was produced against synthesized peptide derived from human BID. AA range:44-93
Subcellular Location
Cytoplasm . Mitochondrion membrane . Mitochondrion outer membrane . When uncleaved, it is predominantly cytoplasmic. .
[BH3-interacting domain death agonist p13]: Mitochondrion membrane . Associated with the mitochondrial membrane. .
[BH3-interacting domain death agonist p15]: Mitochondrion membrane . Translocates to mitochondria as an integral membrane protein. .
[Isoform 1]: Cytoplasm .
[Isoform 2]: Mitochondrion membrane . A significant proportion of isoform 2 localizes to mitochondria, it may be cleaved constitutively. .
[Isoform 3]: Cytoplasm .
Iso type
IgG
Tissue Source
Rabbit
Reactivity
Human
Mouse
Rat
Human Gen
637
Observed Band
25kD
Other Name
BH3-interacting domain death agonist
BID
BID
p22 BID
Background
CASP8 cleaves this encoded protein, and the COOH-terminal part translocates to mitochondria where it triggers cytochrome c release. Multiple alternatively spliced transcript variants have been found, but the full-length nature of some variants has not bee
This gene encodes a death agonist that heterodimerizes with either agonist BAX or antagonist BCL2. The encoded protein is a member of the BCL-2 family of cell death regulators. It is a mediator of mitochondrial damage induced by caspase-8 (CASP8)